Summit Therapeutics Inc (NAS:SMMT)
$ 20.295 -0.465 (-2.24%) Market Cap: 14.97 Bil Enterprise Value: 14.87 Bil PE Ratio: 0 PB Ratio: 34.40 GF Score: 30/100

Q4 2023 Summit Therapeutics Inc Earnings Call Transcript

Feb 20, 2024 / 02:00PM GMT
Release Date Price: $3.74 (-26.23%)
Operator

Hello, everyone. First and foremost, we'd like to apologize for the delay of this event.

Good morning, and welcome to Summit Fourth Quarter and Year End 2023 earnings call. All participants, all participants will be able to will be able to listen only until the question-and-answer portion of this call. We do not expect any technical difficulties today for worried However, in the event that we lose the webcast connection and we are unable to provide any updates, lease rate up to 10 minutes for resolution, please refer to the company's website for updates. Please note that today's call is being recorded. (Operator Instructios)

At this time, I would like to turn the call over to Dave Gancarz, Summit Therapeutics, Chief Business and Strategy Officer. You may now proceed, please.

David Ganzarcz
Summit Therapeutics Inc - Chief Business & Strategy Officer

Good morning, and thank you for joining us. Our press release was issued earlier this morning and is available on the homepage of our website. Our Forms 10K and S. three were also filed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot